NCT00907166 2017-03-21A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer PatientsCornerstone PharmaceuticalsPhase 1/2 Terminated6 enrolled